Our company is recognized for excellence in providing ISO 9001monoclonal and polyclonal antibodies, antigens, enzymes, and purified proteins to the research and medical diagnostic marketplace. Nearly all of our products are validated for usage in quantitative sandwich immunoassay and qualitative rapid testing.
We offer immunological reagents worldwide for diagnostics & research in the following disciplines:
We are happy to inform you that Advanced ImmunoChemical is now offering a set of antibodies produced In vitro. In addition, some of our current antibodies are now available both as In vivo- and In vitro-produced products.
Monoclonal antibodies and mammalian antigens for detecting infectious diseases, cardiac biomarkers, and hormones.
Broad selection antibodies and inactivated viral antigens to detect Influenza A and B in clinical samples.
Monoclonal antibodies for the detection of biological threats and dangerous pathogens.
Biomarkers for cardiovascular disease prevention, risk assessment, and diagnostics.
Customers Include: Princeton University, Duke University School of Medicine, Columbia University Medical Center, CDC, National Institutes of Health, Naval Health Research Center, Los Alamos National Laboratory, US Army Medical Research Institute of Infectious Diseases, Sandia National Laboratories, Stanfored Medicine, NIST, NIMH, Harvard Medical School, Yale University School of Medicine, John Hopkins School of Medicine, Lawrence Livermore National Laboratory, and many more!
Advanced ImmunoChemical is a WBENC-certified woman-owned small business, since 1986.
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Independent biotechnology consulting. All topics related to drug discovery in the therapeutic areas of oncology, cardiovascular, angiogenesis, and inflammation. Expertise in additional areas of Ophthalmology (diabetic retinopathy, macular degeneration) Assistance in research planning and protocols, contracts with academic and commercial laboratories, editing and preparation of manuscripts, grant applications, research strategy, protocols for cell based assays, pharmacodynamic assays, and biomarker studies.
Invivotek LLC, a member of Genesis Biotechnology Group® (GBG) is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013.
Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.
Northwest Life Science Specialties, LLC (NWLSS) is a laboratory research products company focused exclusively on redox biology and oxidative stress. We are committed to helping researchers understand the significance of cellular redox landscape and oxidative stress in medical, environmental and agricultural investigations.
Our major product offering is a line of assay kits and antibodies for detecting and quantifying of various parameters commonly associated with oxidative stress. NWLSS brand products include more than 50 different test kits for detecting biomarkers of macromolecular oxidation, antioxidant status and inflammation. These products are sold worldwide directly to customers or through a growing network of international distributors. With a very broad range of applicability, NWLSS' customers include research laboratories from many of the worlds most respected academic, corporate and government institutes.